Results 181 to 190 of about 51,393 (297)

Prion and Prion Diseases

, 2020
This review article provides the main information regarding a specific category of infectious diseases of animals and humans, the so-called transmissible spongiform encephalopathies, or prion infections. In a brief introduction explains the need for lighting issues in relation to environmental, veterinary public health importance in traffic and the ...
openaire   +1 more source

The cellular prion protein and its role in Alzheimer disease

, 2009
The cellular prion protein (PrPC) is a membrane-bound glycoprotein especially abundant in the central nervous system (CNS). The scrapie prion protein (PrPSc, also termed prions) is responsible of transmissible spongiform encephalopathies (TSE), a ...
Cuadrado-Tejedor, M. (Mar), Irujo, A. (A.), Moleres, F.J. (Francisco J.), Velayos, J.L. (José Luis), Ferrer, V. (Vicente), Paternain, B. (B.)   +5 more
core  

Authorship and citation trends in dementia research: A path to equitable career development for scientists

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION Women are increasingly entering the dementia research workforce, but they frequently fail to attain senior leadership positions in academia. Discrepancies in academic research outputs were investigated to guide equity‐focused policy recommendations.
Jayalakshmi Viswanathan, Diana Karamacoska, Lokendra S. Thakur, Mouna Sawan, Angela Gomez‐Arboledas, Ines Moreno‐Gonzalez, C. Elizabeth Shaaban, Sadaf A. Milani, Giedre Milinkeviciute, Samantha M. Loi, Anika Wuestefeld, Sindhuja T. Govindarajan, Audrey Low, Giovanna Carello‐Collar, Hom L. Shreshta, Sunnie Kenowsky, Claudia K. Suemoto, Michelle M. Mielke, Shana D. Stites   +18 more
wiley   +1 more source

Analysis of Single Particles of Amyloid Beta and α‐Synuclein With Seeded Amplification for the Diagnosis of Alzheimer's and Parkinson's Disease

Biotechnology and Applied Biochemistry, Volume 73, Issue 3, Page 1115-1124, June 2026.
ABSTRACT Neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD), are characterized by the pathological aggregation of specific proteins such as amyloid beta (Aβ) and α‐synuclein, respectively. Early detection of these protein aggregates in biological fluids could facilitate timely diagnosis and therapeutic ...
Alexandra Dybala, Marlene Pils, Oliver Bannach, Gültekin Tamgüney, Detlev Riesner   +4 more
wiley   +1 more source

A fixed brain seeded amplification assay to complement neuropathological prion disease diagnosis. [PDF]

J Neuropathol Exp Neurol
Lewis V, Ellett L, Lei E, Stehmann C, Birchall I, Senesi M, McLean C, Collins SJ.   +7 more
europepmc   +1 more source

The psychological experience of living at risk of an autosomal dominant neurological condition: A scoping review

Alzheimer's &Dementia: Behavior &Socioeconomics of Aging, Volume 2, Issue 2, June 2026.
Abstract As our understanding of genetic risk and the availability of genetic testing increases, consideration of the psychological impact of living at risk for an autosomal dominant neurological condition (ADNC) becomes more pertinent. A systematic search of PsycINFO, MEDLINE, and Web of Science was run to identify studies exploring the psychological ...
Rhianna Brien, Simon Mead, Marc Tibber, Edgar Chan   +3 more
wiley   +1 more source

When prion disease Isn't suspected: prion disease as the cause of terminal decline in chronic mixed dementia. [PDF]

Neurocase, 2023
Krishnamurthy S, Harrison W, Craft S, Lockhart SN, Bateman JR.   +4 more
europepmc   +1 more source

5‐Hydroxytryptamine Distribution Alteration in Both Neuron and Synapse of Tg(SOD1*G93A)1gur Mice: A Potential Intervention Candidate Strategy for Amyotrophic Lateral Sclerosis

CNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
This study reveals that 5‐hydroxytryptamine (5‐HT) synapses in the spinal cord and 5‐HT neurons in the brainstem of the SOD1‐G93A amyotrophic lateral sclerosis (ALS) mouse model are significantly altered, showing a decrease in pre‐symptomatic stages but a marked increase as the disease progresses.
Lijun Zhou, Menghua Li, Qi Dai, Xiwang Liu, Cheng Li, Huifeng Jiao, Haili Pan, Renshi Xu   +7 more
wiley   +1 more source

DL‐3‐n‐Butylphthalide Protects Against PrP106−126‐Induced Neurotoxicity Through NRF2 Signaling and OPA1/DRP1‐Mediated Mitochondrial Dynamics

CNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
NBP counteracts PrP106‐126‐induced neurotoxicity by activating NRF2 and restoring OPA1/DRP1‐mediated mitochondrial dynamics. It suppresses oxidative stress and preserves mitochondrial function and bioenergetics. These actions support NBP as a promising therapeutic candidate for prion‐related neurodegeneration.
Wei Wu, Xixi Zhang, Mingyue Jiang, Ning Ma   +3 more
wiley   +1 more source

Progress of Immunotherapies in Parkinson's Disease

CNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
Parkinson's disease (PD) is caused by an immune disorder triggered by α‐synuclein, leading to a persistent neuroinflammatory cycle that drives the disease from non‐motor symptoms to the motor stage. Second, it presents active and passive immunotherapy strategies targeting α‐synuclein and their potential in slowing down the disease progression.
Yong Peng, Xu‐hui Kang, Shun‐yu Yao, Xiuli Zhang, Sugimoto Kazuo, Jia Liu, Miao‐qiao Du, Lan‐xin Lin, Dai‐yi Jiang, Quan Chen, Hong Jin   +10 more
wiley   +1 more source